Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) Operating Income (2020 - 2025)

Historic Operating Income for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$4.8 million.

  • Gain Therapeutics' Operating Income fell 732.93% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.6 million, marking a year-over-year increase of 1797.26%. This contributed to the annual value of -$20.4 million for FY2024, which is 854.95% up from last year.
  • Per Gain Therapeutics' latest filing, its Operating Income stood at -$4.8 million for Q3 2025, which was down 732.93% from -$5.1 million recorded in Q2 2025.
  • Gain Therapeutics' 5-year Operating Income high stood at -$2.5 million for Q1 2021, and its period low was -$8.2 million during Q2 2024.
  • Moreover, its 5-year median value for Operating Income was -$4.6 million (2022), whereas its average is -$4.7 million.
  • As far as peak fluctuations go, Gain Therapeutics' Operating Income crashed by 56005.52% in 2021, and later surged by 3780.23% in 2025.
  • Over the past 5 years, Gain Therapeutics' Operating Income (Quarter) stood at -$3.2 million in 2021, then crashed by 42.15% to -$4.6 million in 2022, then grew by 3.38% to -$4.4 million in 2023, then rose by 24.42% to -$3.3 million in 2024, then plummeted by 43.67% to -$4.8 million in 2025.
  • Its last three reported values are -$4.8 million in Q3 2025, -$5.1 million for Q2 2025, and -$4.4 million during Q1 2025.